Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

131.70 +2.98 (+2.32%)
Streaming Delayed Price Updated: 10:57 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Neurocrine Biosciences, Inc. - Common Stock

News headline image
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
News headline image
The 5 Stocks Most Sold By Insiders This Year
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
Via MarketBeat
News headline image
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
News headline image
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat
News headline image
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
Via FinancialNewsMedia
Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.